Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Consolidated Net Income: 2018-2024

Historic Consolidated Net Income for Pharming Group N.V (PHAR) over the last 7 years, with Dec 2024 value amounting to -$12.0 million.

  • Pharming Group N.V's Consolidated Net Income rose 1255.41% to $90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.8 million, marking a year-over-year increase of 495.63%. This contributed to the annual value of -$12.0 million for FY2024, which is 283.16% down from last year.
  • Latest data reveals that Pharming Group N.V reported Consolidated Net Income of -$12.0 million as of FY2024, which was down 283.16% from -$3.1 million recorded in FY2023.
  • In the past 5 years, Pharming Group N.V's Consolidated Net Income registered a high of $37.7 million during FY2020, and its lowest value of -$12.0 million during FY2024.
  • Its 3-year average for Consolidated Net Income is $2.5 million, with a median of -$3.1 million in 2023.
  • As far as peak fluctuations go, Pharming Group N.V's Consolidated Net Income spiked by 418.42% in 2022, and later slumped by 283.16% in 2024.
  • Over the past 5 years, Pharming Group N.V's Consolidated Net Income (Yearly) stood at $37.7 million in 2020, then crashed by 118.70% to -$7.1 million in 2021, then spiked by 418.42% to $22.5 million in 2022, then plummeted by 113.90% to -$3.1 million in 2023, then crashed by 283.16% to -$12.0 million in 2024.